Register for IPO Updates
US IPO Stats
IPO Industry Breakdown
Largest Global IPOs
Largest US IPOs
IPO News Archive
New Ways to Invest in IPOs - IPO ETFs
US IPO Weekly Recap: IPO market largely closed; two biotechs go public and break
Analyst IPO Market Commentary
The IPO market was poised to raise $1.4 billion from four IPOs this past week, but instead two biotechs raised $145 million. A substantial portion of those proceeds came from insiders, and both biotechs broke issue with an average loss of 17%.
With markets off and volatility up; it is more difficult for issuers and IPO buyers to find agreeable price. So far,
no operating companies have gone public in 2016
. All four biotech IPOs this year have leaned on insiders to get done, and
each trades below its offer price
Two biotechs break: Enough to end the biotech boom?
Underwritten by Goldman, early-stage gene therapy biotech
) raised $95 million - 12% more than anticipated - and closed its first day down 10%. At least 20% of proceeds were from existing investors, which included Deerfield, PBM Capital and Venrock. Gene therapy peers REGENXBIO (
) and Dimension Therapeutics (
) have lost 40% and 54%, respectively, from their 2H15 IPOs. Cystic fibrosis biotech
) slashed its offer price and increased shares to raise $50 million - at least 40% from insiders - and proceeded to decline 17% on its first day. It finished Friday at $6.18, a 23% loss. Of note, the biotech's top two peers (Nivalis and ProQR Therapeutics) are worth less than the cash on their balance sheets.
Airport food doesn't take off; waste services thrown in the trash heap
Putting iPads in airports, concession operator
) postponed a $553 million deal at a $1.7 billion market value. Based in New York, the highly-levered company has an aggressive growth strategy (+40% in 2015) that targets food contracts for entire airport terminals but also results in lumpy revenue and a high cash burn.
Advanced Disposal Services
), one of the largest private solid waste companies in the US, postponed its $450 million IPO at a proposed market cap of $1.5 billion; IPO proceeds were also slated to pay down its high level of debt. Insiders intended to sell on both offerings.
California construction company
) and Norway-based REIT
Nordic Realty Trust
) had been on the
as day-to-day since January, but officially postponed their IPOs this week.
Two biotechs priced during the week of February 8, 2016
Deal size ($mm)
IPO price vs. midpoint
Return at 2/12
Biotech: Gene therapy for rare disease
Proteostasis Therapeutics (
Biotech: Cystic fibrosis
With a shortened work week and companies updating year-end financials, there are no IPOs on the calendar for next week.
IPO Pipeline update: US Foods files for an estimated $1 billion IPO
After a wave of initial filings from biotechs through mid-January, filing activity has slowed in the past three weeks. LBO'd by KKR and CD&R, US Foods Holdings (
), the 10th-largest private company in the US based on revenue, filed for an IPO that we estimate could raise $1 billion or more. The last $1 billion IPO, KKR's First Data (
), is down 41% from its offer price.
IPO Market Snapshot
The Renaissance IPO Indices are market cap weighted baskets of newly public companies. The Renaissance IPO Index is down 22% year-to-date, compared to -9% for the S&P 500. Renaissance Capital's
(NYSE: IPO) tracks the index, and
top ETF holdings
include Synchrony Financial (
), Alibaba (
) and Citizens Financial Group (
). The Renaissance International IPO Index is down 16% year-to-date, while the ACWX is down 11%. Renaissance Capital’s International
(NYSE: IPOS) tracks the index, and
top ETF Holdings
include Japanese staffing firm Recruit Holdings and European insurance provider NN Group.
To find out if this is the best ETF for you, visit our
IPO Investing page
Keywords / Tickers:
Recently Priced IPOs
ETF Express Award:
ETFExpress awards are based on a 'peer review system' whereby readers - including institutional and high net worth investors as well as managers and other industry professionals at fund administrators, brokers, custodians and advisers - are invited to elect a 'best in class' in a series of categories via an online survey. In each category, the firms with the most votes at the end of the voting period are subject to a final review by ETFExpress's Senior Editorial team.
Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than the original cost. Investors should consider the investment objectives, risks, charges and expenses carefully before investing.
As stated in the Prospectus, the total annual operating expenses for the Fund was 3.48%. The Adviser has contractually agreed to keep net expenses from exceeding 2.50% of the Fund's average daily net assets for at least a year from the date of the Prospectus and for an indefinite period thereafter subject to annual re-approval of the agreement by the Board of Trustees.
An investor cannot invest directly in an index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.
Definitions: Net Asset Value (NAV) of the fund is calculated by dividing the total value of all the securities in its portfolio, less any liabilities, by the number of fund shares outstanding. Market Price is current value at which an asset or service can be bought or sold. Premium/Discount is provided to show the comparison of the daily net asset value (NAV) and the midpoint of the closing bid/ask for each of the funds.
Renaissance IPO Index® (IPOUSA)
is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios.
Renaissance International IPO Index® (IPOXUS)
is a stock market index based upon a portfolio of newly public companies listed on non-U.S. exchanges.
The S&P 500® Index (SPX) is a stock market index which includes 500 U.S. listed companies and seeks to capture approximately 80% coverage of available U.S. market capitalization.
Risk Disclosure: Investments in the
Renaissance IPO ETF, symbol "IPO"
Renaissance International IPO ETF, symbol "IPOS"
(the "ETFs"), and the
Global IPO Fund, symbol "IPOSX"
(the "Mutual Fund") are subject to investment risk, including possible loss of the principal amounts invested. The ETFs and the Mutual Fund (the "Funds") invest in companies that have recently completed initial public offerings. These stocks are unseasoned equities lacking trading history, a track record of reporting to investors and widely available research coverage which many result in extreme price volatility. Due to a greater number of IPOs in certain segments, the Funds may also be subject to information technology and financial sector risk, small and mid-capitalization company risk, and, for the Renaissance International IPO ETF, emerging markets risk. The Funds may hold securities in the form of Depository Receipts, REITs, and Partnership Units which have greater risks than common shares. The strategies have high portfolio turnover and securities lending risks. The returns of the ETFs may not match the return of the respective indices. The ETFs are classified as non-diversified investment companies subject to concentration risk.
Prospectus: Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus and/or summary prospectus with this and other information, please visit
. Read the prospectus carefully before investing. Renaissance Capital Investments, Inc., distributor for the Mutual Fund. Foreside Fund Services, LLC, distributor for the ETFs, 1-866-486-6645.
Definitions: The Renaissance IPO Index® is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios. The S&P 500® Index is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE or Nasdaq.
The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital - manager of IPO-focused ETFs.
The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO), the Renaissance International IPO ETF (symbol: IPOS), or the Global IPO Fund (symbol: IPOSX), may have investments in securities of companies mentioned.
Register for Updates
Renaissance Capital LLC is an SEC-registered investment adviser.
Renaissance Capital Investments, Inc. is a
-registered broker-dealer, and member of
© 2017 Renaissance Capital LLC. All rights reserved.